Key facts
- This page summarizes Altchem Ltd's Form 4 filing for RVL Pharmaceuticals plc.
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 23 Oct 2023, 13:06.
Altchem Ltd - 19 Oct 2023 Form 4 Insider Report for RVL Pharmaceuticals plc
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 19 Oct 2023
- Net transaction value
- -$580,147
- SEC form
- 4
- Accepted by SEC
- 23 Oct 2023, 13:06:00 UTC
- Prior SEC filing
- 20 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/MILITSA SYMEOU, Altchem Limited, by Militsa Symeou, its Director
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Altchem Ltd filed Form 4 for RVL Pharmaceuticals plc on 23 Oct 2023.
Change
- Previous filing in this sequence was filed on 20 Oct 2023.
- Current net transaction value: -$580,147.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RVLP
transaction
Ordinary Shares
Sale
- Transaction value
- $431,669
- Shares
- -9,363,760
- Change %
- -49%
- Price
- $0.0461
- Shares after
- 9,700,000
- Date
- 19 Oct 2023
- Ownership
- Direct
- Footnotes
- F1
RVLP
transaction
Ordinary Shares
Sale
- Transaction value
- $148,478
- Shares
- -4,758,899
- Change %
- -49%
- Price
- $0.0312
- Shares after
- 4,941,101
- Date
- 20 Oct 2023
- Ownership
- Direct
- Footnotes
- F2
RVLP
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,182,243
- Date
- 19 Oct 2023
- Ownership
- By Self as Sole Manager of Orbit Co-Invest A-1 LLC
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Altchem Ltd is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0400 to $0.0580, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0300 to $0.0373, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
Represents shares of the Issuer held by Orbit Co-Invest A-1 LLC. Altchem Limited is the sole manager of Orbit Co-Invest A-1 LLC. As a result, Altchem Limited may be deemed to share voting and investment power with respect to the shares held by Orbit Co-Invest A-1 LLC. Altchem Limited disclaims beneficial ownership of such shares and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.